The Children’s Tumor Foundation (CTF) is focused on ending neurofibromatosis (NF) through research. To date CTF has committed over $35M to NF research, ranging from preclinical drug testing to clinical research and a national NF Clinic Network.
Schwannomatosis is the rarest form of NF, affecting 1:40,000 persons and causing peripheral nerve tumors and unmanageable pain.
In 2007 a candidate schwannomatosis gene, INI-1/Smarc-B1/Snf-5 was identified. Harnessing this discovery, over the past several years CTF has i) convened a series of Schwannomatosis Workshops to identify priorities for advancing schwannomatosis research; and ii) funded schwannomatosis research totaling over $1.3 million since 2007. Results from this include the first schwannomatosis mouse models, utilizing these for preclinical drug trials, advancing schwannomatosis genetics, and establishing an international Schwannomatosis Database.
CTF is offering 2014 Schwannomatosis Awards of up to $75,000 each.
Schwannomatosis Awards may be requested for research in any area of relevance to advancing schwannomatosis research in the following priority areas:
- Cell Biology & Translational Research
- Clinical Research
Please check back soon for further updates about Schwannomatosis awards.
If you have questions please contact firstname.lastname@example.org
2014 Schwannomatosis Award Recipients
Dr. Miram Smith, University of Manchester
Dr. James Walker, Harvard Medical School
Developing a Schwannomatosis Cell Model using CRISPR/Cas9 Genome Editing
Recent Schwannomatosis Award Recipients
Dr. Marco Giovannini, House Research Institute
Development of a screening platform for Schwannomatosis therapeutic agents
Dr. Larry Sherman, Oregon National Primate Research Center
Regulation of TRPV1 in sensory neurons by SNF5-null Schwann cells
Dr. Scott R. Plotkin, Massachusetts General Hospital
Neurotrophin levels in schwannomas and schwannomatosis patients: is there a relationship to chronic pain?
Dr. Laura Papi, House Research Institute
Exome Sequencing of schwannomatosis genome
Dr. Betty Tyler, Johns Hopkins Medical Instutute
Creating preclinical models of surgery for spinal schwannomas